Newton, MA, United States of America

Pan Luying


Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Pan Luying

Introduction

Pan Luying is a notable inventor based in Newton, MA (US). He has made significant contributions to the field of genetic therapies, particularly in the development of cell lines for medical applications. His work focuses on advancing treatments for genetic disorders, showcasing his commitment to innovation in healthcare.

Latest Patents

Pan Luying holds a patent for the "Mannose receptor C type 1 (MRC1) codon optimized cell line and uses thereof." This patent describes isolated nucleic acid molecules that comprise a nucleotide sequence encoding the mannose receptor, C type 1 (MRC1). The innovation includes a codon-optimized 5' region of the nucleotide sequence, which enhances the efficiency of the cell line. The patent also outlines methods for detecting antibody production, particularly neutralizing antibody production, in subjects being treated for Gaucher disease using these specialized cells. He has 1 patent to his name.

Career Highlights

Pan Luying is currently employed at Shire Human Genetic Therapies, Inc., where he continues to work on groundbreaking genetic therapies. His role involves research and development aimed at improving treatment options for patients with genetic disorders. His expertise in genetic engineering and cell line development has positioned him as a valuable asset in the field.

Collaborations

Throughout his career, Pan Luying has collaborated with esteemed colleagues, including Juan Ruiz and Marcia Sellos-Moura. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to significant advancements in genetic therapies.

Conclusion

Pan Luying's contributions to the field of genetic therapies exemplify the impact of innovative thinking in medicine. His patent on the MRC1 codon optimized cell line represents a significant step forward in the treatment of genetic disorders. Through his work at Shire Human Genetic Therapies, Inc., he continues to push the boundaries of what is possible in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…